H1299 cell lysate with iscomatrix adjuvant vaccine / National Cancer Institute - LARVOL DELTA

Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies. (PubMed, Transl Lung Cancer Res) - "Eight of 14 patients (57%) exhibited serologic responses to NY-ESO-1. Cyclophosphamide/celecoxib did not appear to increase immune responses or enhance vaccine-induced alterations in peripheral immune subsets. H1299 lysate vaccines with Iscomatrix™ induce immune responses to CTA and modulate peripheral immune subsets in a manner that may enhance antitumor immunity in patients with thoracic malignancies."

Clinical • IO biomarker • Journal • P1 data • P2 data • Immunology • Inflammation • Lung Cancer • Oncology • Solid Tumor • Systemic Inflammatory Response Syndrome • Thoracic Cancer • CD14 • CTAG1B • PD-1 • PD-L1

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum (clinicaltrials.gov) - P1/2; N=21; Terminated; Sponsor: National Cancer Institute (NCI); Trial completion date: Nov 2028 ➔ May 2021; Suspended ➔ Terminated; Vaccine production halted in 2015, re-start timeline is unknown, thus study is terminated.

Clinical • Trial completion date • Trial termination • Esophageal Cancer • Gastrointestinal Cancer • Germ Cell Tumors • Lung Cancer • Melanoma • Oncology • Sarcoma • Solid Tumor • Thoracic Cancer

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum (clinicaltrials.gov) - P1/2; N=21; Suspended; Sponsor: National Cancer Institute (NCI); Trial completion date: Nov 2023 ➔ Nov 2028; Trial primary completion date: Nov 2023 ➔ Nov 2028

Clinical • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Sarcoma • Solid Tumor • Thoracic Cancer

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum (clinicaltrials.gov) - P1/2; N=21; Suspended; Sponsor: National Cancer Institute (NCI); Trial completion date: Nov 2020 ➔ Nov 2023; Trial primary completion date: Nov 2020 ➔ Nov 2023

Clinical • Trial completion date • Trial primary completion date